Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
Open Access
- 11 March 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-11
Abstract
The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and its activity correlates to outcome in cancer patients. The aim of this study was to evaluate serum TK1 activity (sTK1) levels in MBC patients as a tool for prognostication and treatment monitoring. 142 women with MBC scheduled for 1st line systemic treatment were included in a prospective observational study. sTK1 was measured at baseline (BL) and at 1, 3 and 6 months and correlations to progression-free and overall survival (PFS, OS) evaluated. High sTK1 levels (above median) correlated to worse PFS and OS at BL, also after adjusting for other prognostic factors. sTK1 levels were significantly associated with PFS and OS measured from follow-up time points during therapy. Changes from 3 to 6 months during therapy significantly correlated to PFS and OS, whereas early changes did not. We could demonstrate sTK1 level as an independent prognostic factor in patients with newly diagnosed MBC. Changes in sTK1 levels from 3 to 6 months correlated to PFS and OS. Future studies of sTK1 are warranted to further define its clinical utility.Keywords
This publication has 29 references indexed in Scilit:
- Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationBMC Medicine, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTJournal of Clinical Oncology, 2008
- The role of thymidine kinase in cancer diseasesExpert Opinion on Medical Diagnostics, 2008
- Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast CancerThe Oncologist, 2006
- RECIST revisited: A review of validation studies on tumour assessmentEuropean Journal of Cancer, 2006
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI: Journal of the National Cancer Institute, 2005
- Prognostic significance of thymidine kinase activity in bladder carcinomaCancer, 2002
- Tumour marker measurements in the diagnosis and monitoring of breast cancerCancer Treatment Reviews, 2000
- Utility of CA 15-3 and CEA in monitoring breast cancer patients with bone metastases: Special emphasis on “spiking” phenomenaClinical Biochemistry, 1997